Regenxbio (NASDAQ: RGNX) reported Q3 EPS of ($1.37), $0.29 worse than the analyst estimate of ($1.08). Revenue for the quarter came in at $30.8 million versus the consensus estimate of $41.46 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.